
	Where results make sense

Topic: Diosynth

Related Topics

Organon International

Amgen

Akzo Nobel

Alza

Abbott Laboratories

Biogen Idec

Genentech

Bayer AG

List of pharmaceutical companies

OSS

Pharmaceutical

Cephalon

List of cities in the Netherlands

In the News (Fri 11 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	Organon USA
		Diosynth, a business unit of Akzo Nobel, is a science-driven and technology-based manufacturer of complex active pharmaceutical ingredients.
		Diosynth’s operations are backed by a large development organization, strong commitment to Good Manufacturing Practice (cGMP) and strict adherence to HSE legislation.
		Diosynth is headquartered in Oss, the Netherlands, has about 2,700 employees and achieved sales in 2003 of EUR 479 million.
	www.organon-usa.com /news/2004_08_31diosynth_merger.asp (0 words)

	Diosynth
		One of the world’s largest manufacturers of active pharmaceutical ingredients, Diosynth has established an enviable reputation as a reliable partner in process development and manufacturing for the pharmaceutical sector.
		Renowned in the market for its expertise in complex organic chemistry and extractions, Diosynth’s products are used by pharmaceutical companies in the manufacture of drugs to treat a wide variety of ailments and diseases including diabetes, inflammation, hormone deficiency and cancer.
		Diosynth BIotechnology facilities in the U.S and Europe manufacture both commercial drug substance and clinical material for leading biotechnology companies around the world.
	www.akzonobel.com /com/Healthcare/Businesses/Diosynth.htm (0 words)

	Akzo Nobel Pharma
		Diosynth is a science-driven and technology based manufacturer of active pharmaceutical ingredients (APIs) for the third party market.
		Diosynth is renowned for its expertise is complex organic chemistry, extractions, cell culture, fermentation and chromatographic purification, including High Performance Liquid Chromatography (HPLC).
		Diosynth is headquartered in Oss, the Netherlands, and operates production facilities in France, Scotland, Brazil, U.S.A. and the Netherlands.
	www2.akzonobel.nl /pharma/diosynth.asp (0 words)

	Biospace.com (Site not responding. Last check: 2007-09-21)
		As a market-driven and technology-based organization, Diosynth Biotechnology is a leader in process development and cGMP manufacturing of recombinant proteins, monoclonal antibodies, vaccines and peptides in state-of-the-art FDA and EMEA inspected facilities located in the USA and The Netherlands.
		Diosynth, a leader in process development and cGMP production of recombinant proteins/peptides for therapeutic and vaccine applications, has also made an investment in the Company by purchasing $3.5 million of Dendreon common stock in connection with the parties' antigen development agreement.
		Diosynth Biotechnology, Research Triangle Park, NC, USA and Selexis, S.A., Plan-les-Ouates, Switzerland today announced the initiation of a joint research study to evaluate MARtech, a platform for cell line development developed by Selexis, for process development and cGMP manufacturing of recombinant proteins, such as monoclonal antibodies.
	www.biospace.com /news_company.aspx?companyID=696520 (0 words)

	Diosynth taps Swiss tech for protein production
		Contract research manufacturer Diosynth has forged a joint venture with a Swiss firm for a technology that could dramatically reduce the time and cost of developing new cell lines for manufacturing proteins, writes Phil Taylor.
		For Diosynth, this should mean more protein is made per batch, reducing the cost and hiking the efficiency of manufacturing, allowing it to compete more favourably with its competitors.
		Diosynth said it is evaluating the technology at present, with a view to incorporating MARtech into its process development activities, which would provide a revenue stream for Selexis.
	www.outsourcing-pharma.com /news/ng.asp?n=53163-diosynth-taps-swiss (0 words)

	Globeinvestor.com: Vernalis Signs Agreement with Diosynth Biotechnology for Phase III Manufacture of V10153
		In particular, V10153 has the potential to be effective and safe for use for a longer period after the onset of a stroke, enabling a broader group of patients to receive treatment.
		Diosynth Biotechnology is a division of Organon that supplies contract manufacturing services for the global biotechnology industry.
		Diosynth Biotechnology serves pharmaceutical and biopharmaceutical customers globally and operates FDA-, Health Canada- and EMEA-inspected cGMP manufacturing facilities in Research Triangle Park, NC USA, and Oss, the Netherlands.
	www.globeinvestor.com /servlet/ArticleNews/print/BWIRE/20050922/20050922005364 (0 words)

	Diosynth cuts staff in Scotland
		Although he insisted that the long-term future of Diosynth Ltd is secure, Dr Ingram said it was likely to be at least 2006 before work picks up at the plant.
		In addition to the Asian competition and patent loss, Diosynth is being affected by the general downturn in the pharmaceutical industry’s fortunes.
		Dr Ingram also said that new legislation introduced for the chemicals industry has had a detrimental effect on Diosynth, pointing in particular to the new REACH programme, which requires all chemicals manufactured within the EU at over one tonne to be tested and registered.
	www.drugresearcher.com /news/printNewsBis.asp?id=48858 (0 words)

	Entry-Level Nursing Jobs, Healthcare Jobs & Allied Health Jobs
		Diosynth develops manufacturing processes for high value added active ingredients for pharmaceutical companies all over the world by applying advanced technologies while complying with the highest cGMP and HSE standards.
		Diosynth high levels of reliability, which are embedded in our production processes and are constantly monitored throughout our entire organization.
		The way Diosynth Biotechnology is organized allows employees with drive and ambition the space to show what they can do.
	www.campusrn.com /students/honorroll_detail.asp?company_id=4767 (0 words)

	Diosynth Biotechnology is selected by NeoPharm to Produce IL13-PE38QQR for an Important Phase III Trial. - Business ... (Site not responding. Last check: 2007-09-21)
		Diosynth Biotechnology is selected by NeoPharm to Produce IL13-PE38QQR for an Important Phase III Trial.
		NeoPharm has selected Diosynth Biotechnology to manufacture clinical quantities for their important Phase III trial for malignant glioma, a deadly form of brain cancer.
		Diosynth Biotechnology, a unit of Akzo Nobel, is a market-driven and technology-based manufacturer of complex active pharmaceutical ingredients.
	www.highbeam.com /library/docfree.asp?DOCID=1G1:115044250&ctrlInfo=Round18:Mode18c:DocG:Result&ao= (0 words)

	Chemie.DE News-Center: Akzo Nobel's Diosynth announces global restructuring of chemical synthesis operations
		We are experiencing a structural decline in demand at Diosynth and we have to address this accordingly," he added.
		Diosynth is facing a significant rise in overcapacity as a result of a severe decline in demand for active pharmaceutical ingredients (APIs) from its customers.
		Last month Diosynth notified its employees in Buckhaven that as a result of declining demand it intends to reduce the workforce by 75 people.
	www.chemie.de /news/e/35690 (0 words)

	Diosynth Selects Waters NuGenesis SDMS
		Diosynth is one of the largest manufacturers of active pharmaceutical ingredients in the world.
		Diosynth plans to use the Waters NuGenesis SDMS platform as the foundation for their electronic lab notebook.
		Diosynth is headquartered in Oss, the Netherlands, has about 3,000 employees and achieved sales in 2003 of EUR 479 million.
	www.waters.com /watersdivision/contentd.asp?watersit=JLEY-62VKJW (0 words)

	Pharmalicensing.com
		It will also enable Diosynth to increase its market strength as one of the strategic technology platforms of Akzo Nobel Pharma, alongside Organon and Intervet,'' said Paul K. Brons, the member responsible for the Pharma Group on Akzo Nobel's Board of Management.
		Covance is one of the world's largest and most comprehensive drug development services companies with 2000 revenues of $868 million, operations currently in 17 countries, and approximately 7,900 employees worldwide.
		Diosynth, a business unit of Akzo Nobel, is a market-driven and technology based manufacturer of active pharmaceutical ingredients.
	www.pharmalicensing.com /news/adisp/988100182_3ae536562b4db (0 words)

	Diosynth Biotechnology \| Press Releases (Site not responding. Last check: 2007-09-21)
		On April 1, 2005, Frank Tielens assumed the position of President and CEO of Diosynth Biotechnology, which is the Organon third-party contract manufacturing services unit for biopharmaceuticals.
		The appointment of Frank Tielens follows the completion in 2004 of significant large scale manufacturing investments in Oss, the Netherlands, which underscore the strong commitment at Organon to biotechnology in general and to the importance of sustaining and growing the CMO business in particular.
		Diosynth Biotechnology is the Organon third-party contract manufacturing services unit for biopharmaceuticals.
	www.diosynth-rtp.com /news.asp?newsid=24&page=6 (0 words)

	C&EN: TODAY'S HEADLINES - AKZO TO SLASH CAPACITY FOR DRUG CHEMICALS
		Diosynth will reduce global chemical synthesis capacity by closing its site in Mexico City and scaling back facilities in the Netherlands.
		Diosynth is the latest in a string of pharmaceutical chemical makers to scale back capacity.
		Interestingly, in December 2002, Diosynth was on the verge of increasing its capacity with an agreement to acquire GlaxoSmithKline's API plant in Montrose, Scotland.
	pubs.acs.org /cen/topstory/8208/8208akzonobel.html (0 words)

	Diosynth Ltd - Health, Safety and Environmental (Site not responding. Last check: 2007-09-21)
		At the heart of Diosynth’s care programme is the HSE management system, which helps meet legal requirements and Diosynth’s own HSE objectives.
		Diosynth Ltd operates under a PPC license from the Scottish Environment Protection Agency.
		Diosynth Ltd is committed to being a good neighbour and respected member of the local community.
	www.diosynth.co.uk /Pages/HSE/HSE.htm (0 words)

	Job Details: Manager, Sales Development (Contract Administrator), Diosynth RTP Inc. - North Carolina Biotechnology ...
		Diosynth Biotechnology is a dedicated CMO and a leader in technology-driven process development and cGMP manufacturing of recombinant proteins, peptides and monoclonal antibodies.
		Diosynth Biotechnology supplies contract manufacturing services for the global biotechnology industry.
		Diosynth Biotechnology is a division of Akzo Nobel's human healthcare business unit Organon.
	www.ncbiotech.org /jobs/jobdetail.cfm?jobid=5937 (0 words)

	Sample Contracts - Supply Agreement - Diosynth BV and Pharmaceutical Discovery Corp. - Competitive Intelligence for ...
		Diosynth will use its best commercial efforts to deliver as soon as possible any quantities in excess of the purchase order as determined in Article 2.1.
		If Diosynth agrees with PDC's opinion, PDC shall dispose of the defective delivery as Dlosynth shall direct and at Diosynth's expense and Diosynth shall replace such delivery free of charge as soon as practical thereafter.
		If PDC falls to notify Diosynth of its faulty manufacture within thirty (30) days from the date of delivery of any quantity of Product, this delivery shall be deemed to conform to the specifications for the purpose of this Article 4.
	contracts.onecle.com /mannkind/diosynth.supply.2000.01.01.shtml (0 words)

	DENDREON CORP (Form: 8-K, Received: 12/28/2005 15:31:07)
		If despite their good-faith efforts, DENDREON and DIOSYNTH are unable to agree on terms for such services during the 90-day negotiation period, then DENDREON shall have no further obligation under this Section 14.8 and shall be free to utilize any Third Party for the performance of such services.
		DIOSYNTH also warrants: that it does not to the best of its knowledge, and will not knowingly, use in any capacity the services of any person, or organization that employs any person, who has been debarred under section 306 of the Act in connection with the manufacture of the Ancillary Component.
		DIOSYNTH will maintain in effect during the term of this Agreement, any and all federal, state and/or local licenses, applicable regulatory approvals, registrations and permits which may be required to be maintained by DIOSYNTH in order to manufacture the Ancillary Component hereunder.
	investor.dendreon.com /EdgarDetail.cfm?CIK=1107332&FID=1193125-05-249648&SID=05-00 (0 words)

	Diosynth Biotechnology Announces Amendment to Validation and Manufacturing Agreement with NeoPharm, Inc. For ... (Site not responding. Last check: 2007-09-21)
		Diosynth Biotechnology today announced that it has agreed to an amendment of the current agreement it has with NeoPharm, Inc.
		Frank Tielens, Diosynth Biotechnology's President, expressed his gratitude to NeoPharm "for the continued trust shown in us as their contract manufacturer.
		Tielens indicated that Diosynth Biotechnology will use its expertise in process and analytical methods development for the validation of this biotechnology process.
	www.forbes.com /businesswire/feeds/businesswire/2005/09/21/businesswire20050921005756r1.html (0 words)

	Diosynth and Organon to be combined into one. \| Business (Site not responding. Last check: 2007-09-21)
		Diosynth and Organon to be combined into one.
		The main benefits are expected to be the combination of know-how, technologies, people and facilities, reducing complexity and optimising investment decisions The biotechnology activities of Organon and Diosynth will also be merged into a single platform and some analysts view this as the main reason for the rationalisation.
		"Diosynth and Organon to be combined into one." is an article from the Business category.
	www.allbusiness.com /periodicals/article/237343-1.html (0 words)

	Euronext
		Diosynth Biotechnology’s large-scale facility is well suited to supply commercial quantities of rhC1INH.
		Diosynth Biotechnology is Organon’s third-party manufacturing services unit for biopharmaceuticals.
		Diosynth is part of Akzo Nobel’s human healthcare business unit Organon.
	www.euronext.com /news/companypressrelease/0,4616,1679_11894_542472104,00.html (0 words)

	Diosynth Biotechnology Enters Long-Term Commercial Supply Agreement With Dendreon Corporation (Site not responding. Last check: 2007-09-21)
		RESEARCH TRIANGLE PARK, N.C., March 2 /PRNewswire/ -- Diosynth Biotechnology announced today that it has entered into a long-term commercial supply agreement with Dendreon Corporation (Nasdaq: DNDN) for the manufacture of the recombinant antigen component of PROVENGE(R) (sipuleucel-T), Dendreon's investigational active cellular immunotherapy for prostate cancer.
		This agreement reflects a continuing collaboration between Dendreon and Diosynth Biotechnology beginning with the initial agreement for process development and scale-up through the more recent manufacture of conformance lots.
		For more information: http://www.diosynthbiotechnology.com Diosynth Safe Harbor Statement* This press release may contain statements which address such key issues as the Akzo Nobel growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/03-02-2006/0004312346&EDATE= (0 words)

	APO (Site not responding. Last check: 2007-09-21)
		Diosynth Biotechnology, Research Triangle Park, NC, USA and Selexis, S.A., Plan-les-Ouates, Switzerland announced the initiation of a joint research study to evaluate MARtech, a platform for cell line development developed by Selexis, for process development and cGMP manufacturing of recombinant proteins, such as monoclonal antibodies.
		By aligning Selexis with Diosynth Biotechnology, we hope to achieve a broader penetration of the technology in the market place.
		We selected Diosynth Biotechnology based on a number of factors, such as their philosophy and experience in contract manufacturing", noted Igor Fisch, PhD, Chief Executive Officer of Selexis.
	www.americanpharmaceuticaloutsourcing.com /industryNewsArticle.aspx?article=57 (0 words)

	Job Details: Engineer II, Downstream Manuf Sciences, Diosynth RTP Inc. - North Carolina Biotechnology Center
		Diosynth Biotechnology, an Akzo Nobel owned company, has over 80 years of experience manufacturing biologics and extensive experience in technology-based process development of human recombinant proteins.
		Diosynth cultivates an opportunity-based culture in an open atmosphere.
		Diosynth RTP Inc. offers a comprehensive benefits package for our employees, including medical/dental/vision/life, 401(k) with immediate eligibility, company-paid pension plan, tuition reimbursement, flexible spending accounts and generous vacation time.
	www.ncbiotech.org /ncbio/ncindustry/careers/jobs/jobdetail.cfm?jobid=6023 (0 words)

	Diosynth Biotechnology (Morrisville)
		Diosynth Biotechnology is part of Akzo Nobel and provides contract biopharmaceutical development and manufacturing services to customers worldwide.
		We have demonstrated this model with more than 40 customers, representing the entire spectrum from start-up biotechnology to multinational pharmaceutical companies.
		Diosynth Biotechnology serves clients globally from sophisticated FDA- and EMEA-inspected cGMP production facilities in Research Triangle Park, NC, in Oss, The Netherlands and in Gisors, France.
	www.biospace.com /company_profile.aspx?companyID=696520 (269 words)

	WRAL Local Tech Wire: business, technology, biotechnology, and venture capital news from across the southeastern region (Site not responding. Last check: 2007-09-21)
		Akzo Nobel, the Netherlands-based parent of Diosynth and Organon, made the announcement.
		Diosynth and Organon operations were integrated by Akzo Nobel last summer.
		"It's an exciting time at Diosynth Biotechnology and I'm honored to have been selected to continue to lead the company towards its goal of becoming the leading and most trusted biopharmaceutical (contract manufacturing organization) in the industry,” Tielens said in a statement.
	www.localtechwire.com /article.cfm?u=11285 (0 words)

	Akzo cuts staff at Diosynth unit (Site not responding. Last check: 2007-09-21)
		The company said that “overcapacity in the chemical synthesis business is too high to ignore,” as it announced 350 job cuts and a restructuring of Diosynth's worldwide operations.
		Diosynth is facing a significant rise in overcapacity as a result of a severe decline in demand for APIs.
		In the face of declining demand, Diosynth is reducing its worldwide chemical synthesis capacity by closing its production site in Mexico and scaling back facilities in the Netherlands.
	www.drugresearcher.com /news/news-NG.asp?id=50091 (0 words)

	Diosynth wins contract to make imaging agent
		Diosynth Biotechnology, the contract manufacturing subsidiary of Dutch chemicals and pharmaceuticals group Akzo Nobel, has won a new contract to manufacture a cardiovascular imaging agent due to start Phase III testing in 2006.
		The new contract is good news for Diosynth, which has been hard hit by overcapacity in the marketplace for contract production of biopharma ingredients.
		Now, the deal with Diosynth will continue this process development work and scale-up to the manufacturing levels needed for pivotal trials and, if approved, commercial sale of the product.
	www.in-pharmatechnologist.com /news/ng.asp?n=61856-diosynth-agenix-thrombosis-outsourcing-diagnostics (0 words)

Try your search on: Qwika (all wikis)